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Abstract
Background:  The treatment of patients with haematological malignancies by means of
haematopoietic stem cell transplantation (HSCT) is often accompanied by life threatening
infections. With emerging antimicrobial resistance there is an increased need for new agents, with
a beneficial safety profile. Therefore we evaluated the safety of the promising new antimicrobial
peptide human lactoferrrin 1-11 (hLF1-11) in healthy volunteers and patients.
Methods: We undertook a sequential, randomised, double-blind, placebo-controlled study using
ascending single (0.005, 0.05, 0.5, 5 mg) and multiple intravenous doses (0.5, 5 mg) in healthy
volunteers, and open-label, single intravenous 5 mg doses in autologous HSCT recipients.
Results: Single and multiple doses of hLF1-11 were tolerable up to 5 mg intravenously in healthy
volunteers, while 5 mg single dose was tolerable in patients. Elevations in transaminases possibly
related to treatment were reversible and not serious.
Conclusion: The new antimicrobial hLF1-11 is well tolerated in healthy volunteers with repeated
daily doses up to 5 mg. The side-effect profile is very favourable for an antimicrobial, the only
undesirable effect being a possible elevation of transaminases, which may be related to hLF1-11
although the current data do not allow conclusive interpretation of treatment relationship. A lower
dose is recommended for the forthcoming multiple dosing studies in HSCT patients.
Trial registration: ClinicalTrials.gov: nct00509938.
Background
The treatment of patients with haematological malignan-
cies with haematopoietic stem cell transplantation
(HSCT) is often accompanied by life threatening compli-
cations as a result of the damage caused by the condition-
ing regimens to the mucosal barrier, and the innate and
adaptive, humoral and cellular immune defences [1-3].
Despite many advances in supportive care, transplanta-
tion-related morbidity and mortality due to bacterial and
fungal infections and uncontrolled inflammation remains
high [4,5]. A troublesome fact is the increasing resistance
against several important antimicrobial drugs including
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quinolones, azoles and cephalosporins, making control
of bacterial and fungal infections in HSCT a difficult task
[6-8]. Therefore, the discovery of a broad array of naturally
occurring antimicrobial peptides (AMPs) is interesting,
although few AMPs have been studied so far and even less
have been studied in clinical settings [9-11].
Human lactoferrin is a natural defence protein present in
body fluids and secretions as well as neutrophils [12,13],
and has pleiotropic functions including broad spectrum
antimicrobial activity, antitumour activity, regulation of
cell growth and differentiation, and modulation of
inflammatory, humoral and cellular immune responses
[14-17]. Levels of lactoferrin are decreased following
HSCT [18], contributing to the overall immune defi-
ciency. Correcting this deficit might ameliorate immunity
in HSCT recipients [19].
Human lactoferrin 1-11 (hLF1-11) is a lactoferrin deriva-
tive being developed for the treatment of bacterial and
fungal infections in HSCT recipients. It contains the N-ter-
minal moiety of hLF, consisting of 11 amino acids, that is
essential for the antimicrobial and anti-inflammatory
activity [14,15]. Preclinical studies have shown promising
antimicrobial activity even in the setting of immunodefi-
ciency justifying further investigation for clinical applica-
tion [20-24]. Being a derivative of a 'natural' human
protein, hLF1-11 might have the advantage of fewer side
effects and less formation of antibodies and antimicrobial
resistance, especially since antimicrobial peptides are
unlikely to induce resistance because of the evolutionary
difficulty in changing bacterial membrane structure [11].
We report on the first three studies conducted in humans
with ascending doses of hLF1-11 in healthy volunteers
and in patients receiving autologous HSCT following con-
ditioning with high-dose melphalan (HDM) for multiple
myeloma or lymphoplasmocytic lymphoma.
Methods
Study design
The 3 studies were conducted sequentially and included a
total of 56 subjects (placebo: 12; hLF1-11: 44) as follows.
Study 1: single intravenous administration of ascending
hLF1-11 doses (0.005, 0.05, 0.5 and 5 mg) in healthy vol-
unteers; study 2: multiple intravenous administration of
two ascending hLF1-11 doses (0.5 and 5 mg daily for 5
days) in healthy volunteers; study 3: single intravenous
administration of a fixed hLF1-11 dose (5 mg) in patients
undergoing an autologous HSCT (Table 1, Additional file
1).
Blinding and subject selection
Studies 1 and 2 were conducted in healthy volunteers,
both were randomised, placebo controlled, enrolled 48
volunteers in total (placebo: 12; antimicrobial peptide
(AP): 36) (Table 1) and were conducted at the Phase-I
Clinical Pharmacology Unit, Xendo Drug Development
BV, Groningen, The Netherlands, with prior approval by
the appropriate Institutional Review Board (IRB). Entry
criteria were similar for studies 1 and 2, namely subjects
considered healthy during medical screening by a quali-
fied physician, medical history, physical examination,
vital signs, blood and urine evaluations, and 12-lead elec-
trocardiogram (ECG). Age and body mass index (BMI)
entry criteria were 18 to 45 years (study 1) and 1 to 65
years (study 2), and 18 to 30 kg/m2 (study 1) and 18 to 28
kg/m2  (study 2), respectively. All volunteers provided
written informed consent and the studies were conducted
in compliance with current Guidelines on Good Clinical
Practice [25]. Enrolment took place between March and
April 2005 (study 1) and August and September 2005
(study 2). The aims of both studies were to evaluate the
safety, tolerability and pharmacodynamics of intravenous
administration of hLF1-11. Safety parameters were
adverse events, vital signs, changes in ECG, haematology,
clinical chemistry, urinalysis and immunogenicity. Phar-
Table 1: Entry demographics and dosing schedule.
Subjects Mean age 
(SD), years
Mean 
height 
(SD), cm
Mean 
weight 
(SD), kg
Mean BMI 
(SD), kg/
m2
Male/
female, n
Dosing Dose 
(mg)
Placebo, n hLF1-11, n All, n
Study 1 Healthy 
volunteers
24 (5) 185 (6) 79 (9) 23 (3) 32/0 Single 0.005 2 6 8
0.05 2 6 8
0.5 2 6 8
5.0 2 6 8
Study 2 Healthy 
volunteers
32 (12) 183 (7) 78 (12) 23 (3) 16/0 Multiple 0.5 2 6 8
5.0 2 6 8
Study 3 HSCT 
patients
53 (8) 178 (7) 78 (14) 24 (3) 7/1 Single 5.0 - 8 8
12 44 56
BMI = body mass index; hLF, human lactoferrin; HSCT = haematopoietic stem cell transplant.BMC Medicine 2009, 7:44 http://www.biomedcentral.com/1741-7015/7/44
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macodynamics evaluations were conducted during multi-
ple dosing (study 2) at baseline, days 1 and 5: cytokine
release (interleukin (IL)6, IL10, and tumour necrosis fac-
tor (TNF)α) after ex vivo stimulation with lipopolysaccha-
ride (LPS) endotoxin in whole blood.
Study 3 was conducted in autologous HSCT recipients.
The study was open, and enrolled eight patients (Table 1)
between March and October 2006 at the Department of
Haematology, Radboud University Nijmegen Medical
Centre, The Netherlands, with prior approval by the hos-
pital's IRB. Study conduct was in compliance with current
Guidelines on Good Clinical Practice [25]. Entry criteria
were males/females aged 18 years or older who were
admitted to hospital for autologous HSCT after myeloab-
lative therapy with HDM for multiple myeloma or lym-
phoplasmocytic lymphoma, BMI <30 kg/m2, without
serious other pathologies, or history of hepatitis B or C, or
HIV infection. The aim of study 3 was to evaluate the
safety and tolerability of hLF1-11 given as a single intrave-
nous administration (5 mg) on the day of transplantation.
Safety parameters were adverse events, vital signs, changes
in ECG, haematology, clinical chemistry, urinalysis, and
immunogenicity. Safety and tolerability were evaluated by
adverse event reporting, vital signs, changes in ECG, hae-
matology, clinical chemistry, and urinalysis. Adverse
events were graded according the to the Common Termi-
nology Criteria for Adverse Events (CTCv3.0, National
Cancer Institute, Bethesda, MD, USA) [26].
Blinding in studies 1 and 2 was assured by central alloca-
tion of randomisation codes in sealed envelopes, audited
on completion of each study and by supply of study med-
ication in indistinguishable form.
For the pharmacodynamics evaluations, cytokine meas-
urements were analysed in study 2 using validated assays
for each cytokine once prior to dosing and at six time-
points post dosing (5 min, 30 min, 2 h, 4 h, 8 h, and 24
h) on days 1 and 5, while antibodies against hLF1-11 were
measured in all three studies as specific IgG anti-HLF1-11
and IgE anti-hLF1-11 once prior to dosing and at three
timepoints post dosing (days 2 and 3, 5 to 8, and 14 and
15) by validated enzyme-linked immunosorbent assay
(ELISA), centrally by Xendo Biotech Centre, Groningen,
The Netherlands.
Study medication (active and placebo) was supplied by
AM-Pharma BV (Bunnik, The Netherlands) as lyophilised
powder for solution in normal saline (0.9% NaCl solu-
tion) according to dose.
Statistics, assignment and analysis
Treatment allocation was sequential in all studies, with
randomisation lists issued as single blocks of eight (two
placebo, six active) for studies 1 and 2, while there was no
randomisation in study 3. The intention to treat (ITT)
population for safety evaluations was defined in all stud-
ies as all randomised subjects who received any medica-
tion. Data for studies 1 and 2 were analysed by Xendo
Drug Development, Groningen, using SAS version 8.2
(SAS, Cary, NC, USA) and for study 3 by CRM Biometrics
GmBH (Bonn, Germany), who also checked the databases
for the other two studies. Means, standard deviations,
medians, ranges, upper and lower quartiles were calcu-
lated, and parameters were listed by subject, summarised
and evaluated using descriptive statistics.
Results
Subject characteristics and progress through studies
Demographic data for all three studies at entry are dis-
played in Table 1, with pathological characteristics of
patients in study 3 presented in Table 2. One volunteer in
study 2, originally allocated to the placebo group (multi-
ple dosing) received one dose of active drug (5 mg) on day
4 due to an administrative error, and his safety data were
computed in the active group. All other subjects in the
studies received study medication as planned and yielded
complete datasets for safety and other analyses.
Safety and tolerability results
The main adverse events from the safety evaluations are
presented in Table 3 for studies 1 and 2, and Table 4 for
study 3. Overall, intravenous administration of hLF1-11
did not raise safety concerns in either volunteers or
patients. During single dosing in volunteers, all events
blindly rated as possibly related to treatment were
reported once and occurred on placebo and the lowest
hLF1-11 dose (0.005 mg), none being reported on the two
higher doses. During multiple dosing, the commonest
reported events on hLF1-11 were elevations in liver
enzymes (alanine aminotransferase (ALT) and aspartate
aminotransferase (AST)), which were below twice the
upper level of the normal range (ULN; 40 U/l for ALT; 45
U/l for AST) in one volunteer on 0.05 mg and in two vol-
unteers on 5 mg. The third event was below three times
the ULN. Detailed analysis of daily measurements of liver
enzymes, regardless of levels being reported as adverse
events, recorded enzymes levels above the ULN in 1/2 pla-
cebo volunteers and in 3/6 volunteers on 0.05 mg dose,
while levels above the ULN were recorded in 6/7 volun-
teers on 5 mg. All but one of the daily measurements were
below twice the ULN (one ALT measurement was 127 U/
l on day 6; 5 mg dose). All levels were in the normal range
within 7 days thereafter.
In HSCT recipients after conditioning with HDM, as
expected, several events were recorded, ranging from 5 to
35 events per patient (Table 4). Four serious adverse
events (SAEs) were reported, none of which were consid-
ered to be related to hLF1-11, while four non-serious
events were reported in one patient, considered possiblyBMC Medicine 2009, 7:44 http://www.biomedcentral.com/1741-7015/7/44
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related to hLF1-11, and none were reported for the
remaining seven patients.
Other clinical laboratory tests (haematology, biochemis-
try, and urinalysis) did not suggest any treatment-related
abnormalities in any of the three studies. No abnormali-
ties in coagulation tests were seen. Haemodynamic tests
(blood pressure, heart rate) and 12-lead ECGs (including
QT interval) did not yield any treatment-related effects.
None of the HSCT recipients developed signs of haemol-
ysis or unexpected cytopoenias and no abnormalities
regarding engraftment were seen.
Pharmacodynamic evaluations
There were no changes in any of the pharmacodynamic
evaluations in volunteers during single or multiple dosing
or in patients after single dosing. Cytokine measurements
in study 2 (healthy volunteers) showed high variability
intraindividually and interindividually. Levels of IL10
were undetectable in all samples. Release of IL6 and TNFα
on LPS stimulation seemed attenuated with 0.5 and 5 mg;
however this was neither clinically nor statistically signif-
icant. No antibodies against hLF1-11 were detected (IgG
anti-hLF1-11 or IgE anti-hLF1-11) in volunteers or
patients.
Discussion
Bacterial pathogens account for most infections occurring
shortly after transplantation during neutropaenia, when
mucosal barrier injury is most pronounced. Whilst most
patients receive standard antibacterial prophylaxis with
fluoroquinolones, the majority of infections are caused by
Gram-positive bacteria (65% to 75%), mainly viridans
group streptococci and coagulase-negative staphylococci
as observed in all our patients, and in a minority by Gram-
negative pathogens, mostly Enterobacteriaecae  [27]. The
incidence of fungal infections also remains relatively high
affecting up to 15% in allogeneic HSCT, with Candida spe-
cies and Aspergillus fumigatus predominating [27]. Lactof-
errin or derivatives may prove to be a promising versatile
class of agents for managing infectious complications that
arise from HSCT, because of their broad antimicrobial
activity especially in the context of emerging antimicro-
bial resistance to currently used antimicrobial agents.
Additionally, immune modulating and anti-inflamma-
tory properties might attenuate mucosal barrier injury and
graft versus host disease in HSCT, although for now this
remains speculative [19].
The N-terminal moiety of hLF, in particular the first five
amino acids (Gly-Arg-Arg-Arg-Arg), has a high cationic
charge allowing binding to negatively charged molecules
including microbial products such as lipopolysaccharide
(LPS) and CpG motifs of bacterial DNA (CpG-DNA)
[28,29]. These interactions result in microbial cell wall
disruption and direct microbial killing as a result [30].
Additionally, indirect antimicrobial activity is seen
through the intermediary of cells mainly phagocytes cells
(polymorphonuclear cells, macrophages) probably as
result of opsonisation and probably other not yet fully
determined mechanisms [31-33]. Anti-inflammatory and
Table 2: Disease characteristics of patients who underwent haematopoietic stem cell transplant (HSCT).
Patient no. Age (years) Gender Diagnosis, 
stagea
Paraprotein 
type
Bence-Jones Prior 
treatment
Statusb Melphalan 
dose (mg/kg)
SC001 61 M Multiple 
myeloma, III-A
IgG κ Not present VAD, CAD Partial 
response
3.92
SC002 62 F Multiple 
myeloma, III-A
IgG κ Present VAD, CAD Progressive 
disease
5.61
SC003 50 M Multiple 
myeloma, III-A
Light chain κ Present VAD, CAD Minimal 
response
5.19
SC004 55 M Multiple 
myeloma, III-A
IgG κ, light 
chain κ
Not present VAD, CAD Partial 
response
5.13
SC005 45 M Multiple 
myeloma, III-A
Light chain κ Present PAD, CAD Partial 
response
6.25
SC006 39 M Multiple 
myeloma, III-B
IgG κ Not present VAD, CAD Minimal 
response
4.37
SC007 54 M Multiple 
myeloma, II-A
IgG κ Not present Thalidomide, 
dexamethasone, 
CAD
Stable disease 5.07
SC008 61 M Lymphoplasmoc
ytic lymphoma, 
IV-A
IgG κ, light 
chain κ
Present VAD, CAD Minimal 
response
5.13
aStaging by Durie and Salmon criteria [41]; bstatus after previous treatment by International Bone Marrow Transplant Registry and Autologous 
Blood, and Marrow Transplant Registry criteria [42].
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CAD = cyclophosphamide, adriamycin, dexamethasone; PAD = bortezomib, 
adriamycin, dexamethasone; VAD = vincristine, adriamycin, dexamethasone.BMC Medicine 2009, 7:44 http://www.biomedcentral.com/1741-7015/7/44
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immune-modulatory properties have also been largely
related to N-terminal moiety of hLF [14,15,34-36].
hLF1-11, derived from the active N-terminal moiety of
hLF, has been tested in vitro and in vivo showing broad
spectrum activity against the pathogens commonly
involved in infections after HSCT, both bacterial and fun-
gal, similar to human lactoferrin. The activity in preclini-
cal studies was even superior to that of hLF [37]. In vivo
animal experiments indicated that hLF1-11 is highly effec-
tive against Staphylococcus aureus,  Listeria monocytogenes
and antibiotic resistant Acinetobacter baumannii, reducing
bacterial loads in infected organs by 2 to 3 log
[20,23,24,37]. Furthermore, hLF1-11 was effective against
invasive infections from fluconazole resistant and fluco-
nazole sensitive Candida species even in neutropaenic and
lymphopaenic mice [21,22,38]. Regarding immune-mod-
ulatory properties, as for the antimicrobial activity, the
activity of hLF1-11 is expected to be similar albeit more
potent than those reported for hLF, although this has to
be studied in more detail.
In this study, for the first time, the antimicrobial peptide
hLF1-11 has been tested in healthy volunteers and autol-
ogous HSCT recipients. In both populations the drug was
well tolerated with few possibly related side effects. The
reported events consisted predominantly of discomfort at
the injection site, commonly reported with intravenous
drugs. No changes on electrocardiography and in particu-
lar no increase in QT interval was seen. All adverse events
were mild in intensity, reversible without clinical sequel,
not necessitating any intervention. No signs of cytotoxic-
ity were seen, consistent with earlier in vitro data [39], and
in HSCT recipients no changes in engraftment occurred.
Pharmacodynamic evaluation revealed no apparent
changes in the cytokine profiles, suggesting that the
immune-modulatory effects of hLF1-11 do not result in
an unexpected increase in proinflammatory responses.
During multiple dosing, elevations in transaminase levels
were detected and considered related to the study drug in
five subjects, because use of other drugs or alcohol was
not allowed during the study, although elevations were
observed on placebo as well. Similar abnormalities were
observed in one patient receiving the 5 mg dose, followed
by spontaneous and complete recovery. According to the
CTCv3.0 [26], the maximum elevation was observed once
in one patient and was moderate (grade 2/3). Since this
patient was receiving a number of other drugs known to
affect transaminases (Figure 1), this occurred after single
Table 3: Adverse events in healthy volunteers (n = 48).
Placebo, n 
(%)
hLF1-11, 0.005 mg, n 
(%)
hLF1-11, 0.05 mg, n 
(%)
hLF1-11, 0.5 mg, n 
(%)
hLF1-11, 5 mg, n 
(%)
Study 1 (single dosing):
Subjects per group 8 (100) 6 (100) 6 (100) 6 (100) 6 (100)
Diarrhoea - 1 (16.7) - - -
Dizziness - - - - 1 (16.7)
Epistaxis 1 (12.5) - - - -
Feeling cold - 1 (16.7) - - -
Flatulence - - - - 1 (16.7)
Headache 1 (12.5) 1 (16.7) - - 1 (16.7)
Increased appetite 1 (12.5) - - - -
Phlebitis - - - - 1 (16.7)
Purpura - - - - 1 (16.7)
Somnolence 1 (12.5) - - - 1 (16.7)
Study 2 (multiple 
dosing):
Subjects per group 3a (100) 6 (100) 7a (100)
ALT increase - 2 (33.3) 3 (42.9)
AST increase - - 1 (14.3)
Dry skin 1 (33.3) 1 (16.7) -
Hyperhydrosis - 1 (16.7) -
Injection site 
erythaema
1 (33.3) - -
Injection site pain 1 (33.3) - -
Injection site reaction - 2 (33.3) 1 (14.3)
Malaise - 1 (16.7) -
Nausea - 1 (16.7) -
All listed events were rated blindly as possibly related to treatment.
aOne subject in the placebo group (no. 016) received one dose of hLF1-11 5 mg (day 4) due to administrative error, therefore events were 
computed in the 5 mg group.
ALT = alanine aminotransferase; AST = aspartate aminotransferase.BMC Medicine 2009, 7:44 http://www.biomedcentral.com/1741-7015/7/44
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dose and no effects on transaminases had been reported
during single dosing in healthy volunteers but mild eleva-
tions had been recorded after multiple dosing, we consid-
ered this event as possibly related to treatment. A safety
advisory board (independent of investigators) also evalu-
ated the liver enzyme results of all studies and could not
establish a definite relationship between hLF1-11 and ele-
vated transaminases, although it did not rule out such an
effect and advised that a lower dose (0.5 mg) should be
used in the next multiple dosing study in patients, with
close monitoring of liver parameters. This lower dose is
expected not to interfere with the antimicrobial activity of
hLF1-11, shown in preclinical data to be active in the μg/
kg range [22]. Moreover, a recent study emphasised that
even at very low concentrations AMPs with strong mem-
brane-binding activity could disrupt bacteria by reaching
higher membrane-bound concentrations than intuitively
expected [40].
One important evaluation that is missing in our studies is
the pharmacokinetics of hLF1-11, as to date the detection
of the peptide is impossible to quantify in humans, which
makes safety evaluations all the more important. Inability
Table 4: Adverse events in haematopoietic stem cell 
transplantation (HSCT) patients (n = 8).
Event
All recorded events, n 187
All events possibly treatment related, n 4
Events per patient (min to max), n 5 to 35
Severity (% of events)
Mild 58
Moderate 25
Severe 17
Non-serious events possibly treatment related, na 4
Supraventricular extrasystoles 1
ALT increased 1
AST increased 1
γ-Glutarate increased 1
Serious adverse events (SAEs), nb 4
Heart failure/pulmonary oedema 1
Pulmonary infiltrates 1
Hypoxaemia/respiratory insufficiency 2
Treatment-related SAEs, n 0
aAll four events occurred in one patient (no. 001); bthe four SAEs 
occurred in two patients (no. 002 and no. 005).
ALT = alanine aminotransferase; AST = aspartate aminotransferase.
Serum alanine aminotransferase (ALT) levels in haematopoietic stem cell transplantation (HSCT) patients Figure 1
Serum alanine aminotransferase (ALT) levels in haematopoietic stem cell transplantation (HSCT) patients. 
The drugs depicted in figure are the drugs used by the patient experiencing elevated transaminases. day 0 = day of haematopoi-
etic stem cell transplantation; HDM = high-dose melphalan.BMC Medicine 2009, 7:44 http://www.biomedcentral.com/1741-7015/7/44
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to measure hLF1-11 in plasma is partly due to the doses
being so small (0.005 to 5 mg) that the concentrations in
plasma are undetectable by usual methods. In animals,
99mTc-labelled hLF1-11 was rapidly removed from the cir-
culation mainly via the liver and to a lesser extent via the
kidneys. The quantity of 99mTc-labelled peptide in the
liver remained stable during the first hour after injection,
while the plasma half life (in mice) was estimated at
approximately 30 min, yet this may be a underestimation
since some of the peptide may be receptor bound and an
unknown amount may be quickly metabolised. Studies
are ongoing with internally labelled (C14 and tritium)
peptide to determine distribution and metabolism in ani-
mals, while the quantification in humans remains unde-
termined. Nevertheless, the results of this new
antimicrobial in preclinical studies merit further investi-
gations on the applicability of hLF1-11 in humans, partic-
ularly in patients with haematological malignancies, and
were the motivation for the current studies.
Conclusion
The new antimicrobial drug hLF1-11 was well tolerated in
healthy volunteers with repeated daily doses up to 5 mg.
Owing to elevations in transaminase levels being possibly
related to treatment caution is warranted in further stud-
ies, although this potential effect was regarded not clini-
cally serious and reversible without intervention in all
cases to date. Nevertheless, as a precaution, further testing
will be conducted with a lower dose of 0.5 mg in the forth-
coming multiple dosing study in HSCT patients.
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